Harvard Retained Earnings vs Short Term Debt Analysis
HBIO Stock | USD 2.24 0.03 1.32% |
Harvard Bioscience financial indicator trend analysis is much more than just examining Harvard Bioscience latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Harvard Bioscience is a good investment. Please check the relationship between Harvard Bioscience Retained Earnings and its Short Term Debt accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.
Retained Earnings vs Short Term Debt
Retained Earnings vs Short Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Harvard Bioscience Retained Earnings account and Short Term Debt. At this time, the significance of the direction appears to have no relationship.
The correlation between Harvard Bioscience's Retained Earnings and Short Term Debt is 0.09. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Harvard Bioscience, assuming nothing else is changed. The correlation between historical values of Harvard Bioscience's Retained Earnings and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Harvard Bioscience are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Retained Earnings i.e., Harvard Bioscience's Retained Earnings and Short Term Debt go up and down completely randomly.
Correlation Coefficient | 0.09 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Short Term Debt
Most indicators from Harvard Bioscience's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Harvard Bioscience current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.At this time, Harvard Bioscience's Selling General Administrative is very stable compared to the past year. As of the 26th of November 2024, Tax Provision is likely to grow to about 1.1 M, while Discontinued Operations is likely to drop about 1.3 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 67.7M | 60.8M | 60.9M | 48.3M | Total Revenue | 118.9M | 113.3M | 112.3M | 96.8M |
Harvard Bioscience fundamental ratios Correlations
Click cells to compare fundamentals
Harvard Bioscience Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Harvard Bioscience fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 164.9M | 156.3M | 162.3M | 145.4M | 137.4M | 124.6M | |
Total Stockholder Equity | 81.7M | 76.7M | 83.4M | 72.2M | 73.1M | 82.7M | |
Net Debt | 45.5M | 39.7M | 40.5M | 42.3M | 38.5M | 40.4M | |
Cash | 8.3M | 8.3M | 7.8M | 4.5M | 4.3M | 4.1M | |
Other Assets | 2.3M | 8.9M | 12.3M | 7.8M | 8.9M | 5.2M | |
Cash And Short Term Investments | 8.3M | 8.3M | 7.8M | 4.5M | 4.3M | 4.1M | |
Common Stock Shares Outstanding | 37.8M | 38.6M | 40.3M | 41.4M | 42.4M | 33.1M | |
Liabilities And Stockholders Equity | 164.9M | 156.3M | 162.3M | 145.4M | 137.4M | 124.6M | |
Other Stockholder Equity | 218.5M | 221.7M | 225.7M | 229.0M | 232.4M | 193.5M | |
Total Liab | 83.2M | 79.6M | 78.9M | 73.1M | 64.3M | 41.9M | |
Total Current Assets | 53.6M | 51.7M | 61.6M | 51.1M | 49.0M | 53.5M | |
Short Long Term Debt Total | 53.8M | 48.0M | 48.3M | 46.8M | 42.8M | 22.7M | |
Other Current Liab | 9.1M | 7.2M | 10.5M | 7.5M | 12.3M | 6.2M | |
Total Current Liabilities | 25.3M | 21.1M | 25.3M | 23.2M | 26.5M | 17.5M | |
Property Plant And Equipment Net | 4.8M | 4.0M | 3.4M | 3.4M | 8.8M | 4.9M | |
Retained Earnings | (124.6M) | (132.4M) | (132.7M) | (142.2M) | (145.6M) | (152.9M) | |
Accounts Payable | 5.3M | 6.0M | 4.9M | 6.4M | 5.6M | 5.7M | |
Non Current Assets Total | 111.3M | 104.6M | 100.8M | 94.2M | 88.3M | 73.6M | |
Non Currrent Assets Other | 10.7M | 8.9M | 12.3M | 13.6M | 6.5M | 4.1M | |
Net Receivables | 20.7M | 17.8M | 21.8M | 16.7M | 16.1M | 18.5M | |
Common Stock Total Equity | 438K | 444K | 452K | 454K | 522.1K | 407.4K | |
Non Current Liabilities Total | 57.9M | 58.5M | 53.6M | 49.9M | 37.8M | 25.8M | |
Inventory | 22.1M | 22.3M | 27.6M | 26.4M | 24.7M | 19.3M | |
Other Current Assets | 2.5M | 3.4M | 4.3M | 3.5M | 3.9M | 6.2M | |
Property Plant And Equipment Gross | 13.2M | 11.7M | 3.4M | 24.0M | 23.1M | 24.3M | |
Accumulated Other Comprehensive Income | (12.7M) | (13.1M) | (10.0M) | (15.1M) | (14.2M) | (13.5M) | |
Short Term Debt | 6.9M | 3.8M | 5.4M | 5.9M | 8.7M | 9.1M | |
Intangible Assets | 38.4M | 33.2M | 27.4M | 21.0M | 16.0M | 21.5M | |
Common Stock | 438K | 444K | 452K | 454K | 434K | 410.2K | |
Long Term Debt | 46.9M | 46.3M | 45.1M | 43.0M | 30.7M | 20.7M | |
Good Will | 57.4M | 58.6M | 57.7M | 56.3M | 57.1M | 46.4M | |
Property Plant Equipment | 4.8M | 4.0M | 3.4M | 3.4M | 3.0M | 3.5M | |
Current Deferred Revenue | 3.9M | 3.8M | 4.3M | 3.4M | 7.7M | 8.1M | |
Other Liab | 2.1M | 12.2M | 8.5M | 1.6M | 1.8M | 1.7M | |
Net Tangible Assets | 24.3M | (15.1M) | 83.4M | 72.2M | 65.0M | 68.2M | |
Retained Earnings Total Equity | (124.6M) | (132.4M) | (132.7M) | (142.2M) | (128.0M) | (134.4M) | |
Long Term Debt Total | 9.0M | 58.8M | 46.9M | 46.3M | 53.2M | 30.0M | |
Capital Surpluse | 229.2M | 232.4M | 225.7M | 229.0M | 263.4M | 239.3M | |
Deferred Long Term Liab | 2.3M | 2.0M | 1.9M | 590K | 678.5K | 644.6K |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share (0.33) | Revenue Per Share 2.258 | Quarterly Revenue Growth (0.13) | Return On Assets (0.02) |
The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.